Continuing the Conversation: Exploring B-cell Maturation Antigen-Targeted Therapies and Managed Care Considerations for Patients With Multiple Myeloma

Program Description:

This podcast activity will detail considerations for the use of B-cell maturation antigen-directed therapy in multiple myeloma. Faculty experts will present recent and emerging data for B-cell maturation antigen-targeted agents and highlight management considerations as well as current clinical challenges surrounding their use. Strategies to ensure provision of cost-effective treatment for patients with multiple myeloma and the impact on reducing economic burden will also be discussed.

Target audience: Health-system, managed care, oncology, and specialty pharmacists

Activity type: Knowledge

Release date: July 29, 2022

Expiration date: July 29, 2023

Estimated time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma
• Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-359-H01-P. The activity is available for CE credit through July 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:

Speakers Bureau: Oncopeptides, GSK

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: AstraZeneza, Janssen

Consultant: BeiGene

Speakers Bureau: Pfizer

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms